Printer-Friendly Email Page
Start the program at
the bottom of this page
Take Test

Improving the Treatment of Major Depressive Disorder in Older Adults: Clinical Advances and Emerging Therapies
Release Date: March-14-14
Credit Expiration Date: March-14-15
Developer/Facilitator

.
Medium
This activity is intended for consultant and senior care pharmacists as well as other pharmacists involved or interested in senior care pharmacy and the care of older adults with major depressive disorder.
Credit Hours
1.0 Contact Hour of ACPE Credit
Medium
i-Newsletter
Program Description
A CPE-certified online interactive newsletter with highlights from the American Society of Consultant Pharmacists workshop.

An estimated 6.5 million (about 19%) of older adults in the United States suffer from major depressive disorder (MDD), a condition that leads to significant disability and medical comorbidity. In the long-term care setting, up to 35% of older adults suffer from depression. Depression is the most common mental health disorder among older adults. However, MDD is often unrecognized or suboptimally treated in older adults. Numerous antidepressants for the treatment of MDD are available, yet many older adults do not obtain relief from their symptoms because they fail to respond adequately to these medications or experience intolerable side effects. The goal of this continuing education activity is to expand the knowledge, skills, and competency among consultant pharmacists with regard to current and emerging medications for MDD, ultimately improving quality of life for their older adult patients with MDD.

NOTE: This activity was presented on November 22, 2013, in conjunction with ASCP's Annual Meeting and Exhibition.
Learning Objectives
Upon completion of this educational activity, the participant should be able to:
1.
Discuss common comorbidities in older populations that affect MDD treatment decisions.
2.
Recommend second-line adjustments to MDD treatment plans for older adults with MDD by incorporating measurement-based clinical decisions.
3.
Describe potential benefits of novel drug targets under investigation for the treatment of MDD in older adults.
faculty
Lori A. Daiello, PharmD, BCPP
Assistant Professor of Neurology (Research)
Warren Alpert Medical School
Brown University
Cranston, RI

Sumer Verma, MD
Associate Clinical Professor Psychiatry
Boston University School of Medicine
Medical Director, Dementia Service Briarwood
Needham, MA
faculty
It is the policy of the AAFP, ASCP, and NADONA to ensure balance, independence, objectivity and scientific rigor in all of its educational activities including those which are sponsored and cosponsored. All faculty are expected to disclose any significant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services discussed in an educational presentation. The intent of this disclosure is not to prevent a presenter with significant financial interest or other relationship from making the presentation, but rather to provide the audience with information with which they can make their own judgments. It remains for the audience to determine whether the speaker's interests or relationships may influence the presentation with regard to exposition or conclusion. Faculty are also expected to openly disclose any off-label, experimental, or investigational use of drugs or devices in their presentations.

Dr. Daiello has no relevant financial conflicts to disclose.

Dr. Verma has no relevant financial conflicts to disclose.

ASCP:
Ms. Dechevalier has no relevant financial conflicts to disclose.
Dr. Gerber has no relevant financial conflicts to disclose.

MCM:
Kathryn Klobnak, medical writer/editor, has no relevant financial conflicts to disclose.
Leslie Sharp, editorial manager, has no relevant financial conflicts to disclose.

This educational activity may contain discussion of published and/or investigational uses of pharmaceutical agents. Some uses of these agents may not have been approved by the FDA. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Credit Statements
The American Society of Consultant Pharmacists (ASCP) is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This knowledge-based activity, ACPE Universal Activity #0203-9999-14-007-H01-P, has been assigned 1.0 Contact Hour (0.1 CEU).

Participants must view the activity in its entirety, successfully complete the post-test, and submit an evaluation to receive continuing pharmacy education credit.

Credit will be awarded for a score of 80% or better, and a statement may be printed immediately after passing the post-test.

This activity will take approximately 1 hour to complete.
Commercial Support Statements
Supported by an independent educational grant from Forest Pharmaceuticals, Inc.
Instructions
There are no fees for participating in or receiving credit for this online educational activity. This activity is designed to be completed within the time designated on this page; pharmacists should claim only those credits that reflect the time actually spent in the activity.
1.
Review the intended audience, learning objectives, and author disclosures.
2.
Study the educational content online. Be sure to review both written and audio/slide content.
3.
Once completed, continue to post-test. Online, choose the best answer to each test question. To receive a certificate, you must receive a passing score as designated at the top of the test. In addition, you must also complete the Activity Evaluation.
4.
Computer Requirements: Minimum System Requirements: • Pentium III, 600 MHz or Equivalent Processor • 512 MB of RAM • Windows XP, Vista, or 7 • Mac OS X • 800x600 Monitor Resolution • 16-bit Color • 16 bit Sound Card with Speakers
Certificate Fee

$0.00

Disclaimer
The opinions expressed in these educational activities are those of the faculty and do not necessarily reflect the opinions or recommendations of their affiliated institutions, the publisher, American Society of Consultant Pharmacists, or Forest Pharmaceuticals, Inc. Any medications, diagnostic procedures, or treatments discussed by the program presenters should not be used by clinicians or other health care professionals without first evaluating their patients’ conditions, considering possible contraindications or risks, reviewing any applicable manufacturer’s product information, and comparing any therapeutic approach with the recommendations of other authorities.
Printer-Friendly Email Page Start Program as a Guest
Start Program Take Test
By clicking START PROGRAM I acknowledge that I have read the CME/CE information above.